Multiple patient batch production of 195mPt cisplatin and 195mPt carboplatin for use in drug risk assessment and optimisation of patient dose
No Thumbnail Available
Date
2010-08-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Science
Abstract
Platinum chemotherapeutics are used extensively as a first line treatment in
over 28% of all cancers and widely as a second line treatment in combination
with biological markers such as Herceptin. Over 20% of patients will
experience maximum tolerate dose and significant side effects because
dosage is often estimated using unreliable and indirect methods such as
surface area and glomerular filtration rates. We are interested in providing a
molecular imaging tool that allows the physician to screen a patient, monitor
response and drug resistance and to personalise treatment regimes in order to
reduce side effects.
The ability to produce platinum radiopharmaceuticals commercially has
been limited by long and unreliable synthetic processes. We have developed
patent technology for the production of reactor base platinum radiopharmaceuticals,
such as 195mPt-cisplatin and 195mPt-carboplatin. This study
reports the neutron activation of 194platinum target material in the new
research reactor OPAL and validation of the production of multiple (five)
patient batches for both 195mcisplatin and 195mcarbplatin. Yields were
53±3% and 29±4%, respectively, with specific activities of up to 8MBq/mg.
Production times were dramatically reduced from up to 24 h to less than 3 h
using the new process.© 2010, Elsevier Ltd.
Description
Keywords
Patients, Neoplasms, Filtration, Human populations, Monitoring, Tolerance
Citation
Perkins, G., & Smith, S.V. (2010). Multiple patient batch production of 195mpt cisplatin and 195mpt carboplatin for use in drug risk assessment and optimisation of patient dose. Nuclear Medicine and Biology, 37(6), 726. doi:10.1016/j.nucmedbio.2010.04.145